icon-folder.gif   Conference Reports for NATAP  
 
  The International Liver Congress™
EASL 2017 - European Association for the
Study of the Liver
Amsterdam, The Netherlands. 2017
Back grey_arrow_rt.gif
 
 
 
The Safety and Tolerability of SOF/VEL/VOX for 8 or 12 Weeks in >1000 Patients Treated in the POLARIS-1, POLARIS-2, POLARIS-3, and POLARIS-4 Studies: an Integrated Analysis
 
 
  Reported by Jules Levin
EASL 2017 April 19-23 Amsterdam Netherlands
 
Michael Manns,1 Edward J. Gane,2 Bernard E. Willems,3 Stuart K. Roberts,4 Steven Flamm,5 Marc Bourliere,6 Tarik Asselah,7 Laurent Alric,8 Robert H. Hyland,9 Luisa M. Stamm,9 K.C. Huang,9 Diana M. Brainard,9
Mandana Khalili,10 Graham R. Foster,11 Stuart C. Gordon,12 K. Rajender Reddy,13 Stefan Zeuzem,14 Ira M. Jacobson,15 Curtis L. Cooper,16 Alex J. Thompson,17 Kris Kowdley,18 Eric Lawitz19
1Medizinischen Hochschule Hannover, Germany; 2Auckland Clinical Studies Ltd, Auckland, New Zealand; 3Centre Hospitalier de l'Universite de Montreal, Quebec, Canada; 4The Alfred, Melbourne, Victoria, Australia; 5Northwestern University, Chicago, Illinois, USA; 6Hopital Saint Joseph, Marseille, France; 7Hopital Beaujon, Universite Paris Diderot-Paris 7, Clichy, France; 8Hopital Purpan, Universite Toulouse III-Paul Sabatier, Toulouse, France; 9Gilead Sciences, Inc., Foster City, California, USA; 10University of California San Francisco;
11The Royal London Hospital, London, UK; 12Henry Ford Health System, Detroit, Michigan, USA; 13University of Pennsylvania, Philadelphia, USA; 14Universitätsklinikum Frankfurt, Goethe University, Frankfurt, Germany; 15Mount Sinai Beth Israel, New York, New York, USA; 16Ottawa Hospital Research Institute, Ottawa, Ontario, Canada; 17St Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia; 18Swedish Medical Center, Seattle, Washington, USA; 19Texas Liver Institute, The University of Texas Health Science Center at San Antonio, USA

0426171

0426172

0426173

0426174

0426175

0426176

0426177